Understanding the Evolving Continuing Medical Education Needs of Physicians Managing Patients With TD

CNS Spectrums (05/10/21) Wiley, Shereta; Cerenzia, Wendy; Stacy, Sylvie; et al.

The evolving continuing medical education (CME) needs of physicians treating patients with tardive dyskinesia (TD) were evaluated through a case-based and updated survey of U.S.-practicing psychiatrists and neurologists. The case-based poll of 213 psychiatrists and 187 neurologists was conducted in May 2018, while the updated poll of 125 psychiatrists and 128 neurologists was conducted in March 2020. In both years, less than half of physicians could correctly identify TD prevalence in patients on maintenance antipsychotics. They were moderately familiar with VMAT2 inhibitor therapies, with more neurologists than psychiatrists self-reporting familiarity since the 2018 survey. The data indicated that psychiatrists are more likely to assume responsibility for medical management of TD symptoms and antipsychotic drug adjustment compared with neurologists. Contrary to American Psychiatric Association guidelines and American Academy of Neurology reviews, 15 percent of physicians indicated they would manage TD symptoms with an anticholinergic, while only about 50 percent would choose an VMAT2 inhibitor. Compared with psychiatrists, VMAT inhibitor use grew among neurologists between 2018 and 2020. The findings highlight the need for CME about TD, targeting specific provider groups, the researchers conclude. In particular, they noted the need for CME involving treatment updates among psychiatrists.

Read More

Recent Stories
Alliance Podcast Episode 18: Spotlight on Leadership

Comparison of In-Person Versus Tele-Ultrasound Point-of-Care Ultrasound Training During the COVID-19 Pandemic

Rockpointe Presents Online CME Course on Treating High-Risk Patients With COVID-19